Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protozoa in the intestinal lumen are single-celled eukaryotic organisms residing within the cavity of the human gastrointestinal tract. They exist as either harmless commensals or pathogens causing various gastrointestinal illnesses. Pathogenic species such as Entamoeba histolytica and Giardia lamblia can lead to significant morbidity. Transmission occurs primarily through the fecal-oral route, and diagnosis involves microscopic examination of stool samples.
Metronidazole and Tinidazole: Disrupt protozoal DNA and inhibit nucleic acid synthesis; Nitazoxanide: Inhibits pyruvate:ferredoxin oxidoreductase (PFOR) enzyme pathway; Paromomycin: Inhibits protein synthesis by binding to the 16S rRNA of the protozoal ribosome
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protozoa in the Intestinal Lumen.